Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Go back to Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer| Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) | Delayed: 47.09 +0.45 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.64 | 52 Week High | $4.38 | |||
| Open | $47.13 | 52 Week Low | $1.88 | |||
| Day High | $47.51 | P/E | N/A | |||
| Day Low | $46.49 | EPS | $-1.12 | |||
| Volume | 164,839 | |||||
